Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Maintains Buy Rating on Emerald Holding with Revised Price Target

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
Finance_Financialization
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

Analyst Barton Crockett at Rosenblatt is maintaining a Buy rating on Emerald Holding (NYSE:EEX) with a revised price target of $8.2, down from $8.4. This adjustment reflects a positive outlook on the company’s future performance.

Emerald Holding has shown impressive growth, with a 17% increase in revenue and a 67% rise in adjusted EBITDA in 2023. The company specializes in organizing business-to-business trade shows in sectors such as gift, home, sports, design, and technology. Despite some challenges in capital utilization, Emerald Holding boasts an ROCE of 2.2%.

Overall, the company’s recent financial results and analyst recommendations present a mixed but potentially lucrative investment opportunity.

EEX Stock Shows Strong Performance with Significant Price Increase on March 1, 2024

On March 1, 2024, EEX stock showed strong performance with a significant increase in its share price. According to data from CNN Money, EEX is currently trading in the middle of its 52-week range and above its 200-day simple moving average.

The price of EEX shares increased by $0.45 since the market last closed, representing an impressive 8.40% rise. The stock opened at $5.29, which was $0.07 lower than its previous close. Despite the lower opening price, EEX quickly gained momentum and saw a substantial increase in value throughout the trading day.

Investors may have been drawn to EEX on March 1st due to its strong price momentum and positive performance indicators. The stock’s ability to trade above its 200-day moving average suggests that it is in an upward trend and could continue to see growth in the future.

It is important for investors to conduct their own research and consider their investment goals before making any decisions. While past performance is not indicative of future results, the positive price movement of EEX on March 1st may be a promising sign for those considering investing in the stock.

EEX Stock Performance on March 1, 2024: Total Revenue Up, Net Income Down

On March 1, 2024, EEX stock experienced mixed performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $382.80 million, showing a 17.46% increase compared to the previous year. However, the total revenue for the fourth quarter was $101.50 million, remaining flat compared to the previous quarter.

In terms of net income, EEX reported a loss of $50.20 million for the past year, representing a significant decrease of 171.1% compared to the previous year. On the other hand, the net income for the fourth quarter was reported at a loss of $28.70 million, showing no change compared to the previous quarter.

Unfortunately, the earnings per share (EPS) for EEX were not available at the time of reporting, indicating that there was not enough data to provide insights into this metric.

Overall, the financial performance of EEX on March 1, 2024, showed a mixed picture with a significant increase in total revenue for the year but a decrease in net income. Investors and analysts may need to closely monitor the company’s future financial reports to assess its overall performance and make informed investment decisions.

Tags: EEX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ Chart Down

Analyst Adjusts Price Target for MVB Financial Diverse Opinions in the Financial Industry

Finances

Analyst Adjusts Price Target for Bakkt Holdings Maintains Buy Rating

Technology Cloud computing Trading online

Analyst Reaffirms Buy Rating for Micron Technology Sets Price Target at 105

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com